Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
“We are very disappointed in the topline results in the STARS study that did not meet the study endpoints,” said Ravi Anand, Newron’s chief medical officer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
Gilead announced topline results from the open-label, Phase III SIMPLE trial looking at 5-day and 10-day dosing of the drug in hospitalized patients with severe disease. It also reported positive data from the National Institute of Allergy and Infectious Diseases’ trial of the drug in COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
PRESS RELEASES